Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
- Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
- "Today we presented data from our recommended Phase 2 dose cohort from the ALEXANDER trial of AUTO3, a CD19 and CD22 dual targeting CAR T product candidate in DLBCL.
- The data support a best in class profile with a high level of complete remissions and a well tolerated safety profile," said Dr.Christian Itin, chairman and chief executive officer of Autolus.
- As of the data cut-off date of August 3, 2020, 35 patients in the ALEXANDER Phase 1/2 clinical trial of AUTO3 have been treated and were evaluable for safety.